Humulin NPC, 100 me/ml suspension 3 ml cartridges 5 pcs

Type 2 diabetes, Type 1 diabetes

– Diabetes mellitus with indications for insulin therapy.
– Newly diagnosed diabetes mellitus.
– Pregnancy in type 2 diabetes mellitus (insulin-independent).

Composition

1 ml of suspension for subcutaneous administration contains:

active ingredient:

insulin isophane (human genetically engineered) 100 IU,

auxiliary substances:

Methacresol,

Glycerol,

Phenol,
.

protamine sulfate,

sodium hydrophosphate,

Zinc oxide,

water for injection,

Hydrochloric acid 10% and sodium hydroxide solution 10% (to create the correct pH level).

How to take, the dosage

The dose is set by the doctor individually depending on the level of glycemia. The drug should be administered by injection by injection, possibly by injection in m/m. Intravenous injection of Humulin NPC is contraindicated! P/V drug is administered in the shoulder, hip, buttock or abdomen area. The injection site should be alternated so that the same site is not used more than about once/month. Care should be taken when injecting p/k to avoid entering a blood vessel. The injection site should not be massaged after injection. Patients should be trained in the correct use of insulin injection devices.

Regulations for preparation and administration

Humulin NPH vials should be rolled between the palms of the hands 10 times before use and shaken by turning 180° also 10 times to resuspend insulin until it appears as a homogenous cloudy liquid or milk. Do not shake vigorously as this may cause foam to form, which may interfere with proper dose delivery. Vials should be checked carefully. Insulin should not be used if there are flakes in it after mixing, if solid white particles are stuck to the bottom or walls of the vial, creating a frosty pattern effect.

The contents of the bottle should be filled into the insulin syringe corresponding to the concentration of insulin to be injected, and the desired dose of insulin should be injected as directed by the physician. Using the outer cap of the needle, immediately after injection, unscrew the needle and safely destroy it. Removing the needle immediately after injection ensures sterility and prevents leakage, air ingress, and possible needle clogging. Needles should not be reused.

The needles should not be used by others. Vials should be used until they are empty, at which point they should be discarded. Humulin NPC can be injected in combination with Humulin Regular. To do this, the short-acting insulin should be drawn into the syringe first to prevent the longer-acting insulin from going into the vial.

The mixture should preferably be injected immediately after mixing. A separate syringe for Humulin Regular and Humulin NPX can be used to inject the exact amount of each insulin type. Always use an insulin syringe that is appropriate for the concentration of insulin being injected.

Interaction

Hypoglycemic effect of Humulin NPC is decreased by oral contraceptives, corticosteroids, thyroid hormone drugs, thiazide diuretics, diazoxide, tricyclic antidepressants.

The hypoglycemic effect of Humulin NPC is enhanced by oral hypoglycemic drugs, salicylates (e.g., acetylsalicylic acid), sulfonamides, MAO inhibitors, beta-adrenoblockers, ethanol and ethanol-containing drugs.

Beta-adrenoblockers, clopheline, reserpine may mask the symptoms of hypoglycemia.

Pharmaceutical interactions

The effects of mixing human insulin with animal insulins or human insulin produced by other manufacturers have not been studied.

Special Instructions

It is recommended that if the foam injector or cartridge is damaged or lost, the insulin product (any change of insulin must be done with caution and only under the supervision of a physician) in a bottle and a syringe for injecting the product should be available. Conversion of the patient to another type of insulin or to an insulin preparation with a different brand name must take place under close medical supervision. Changes in insulin activity, type (e.g., M3, NPH), species (porcine, human insulin, human insulin analogues) or method of production (DNA recombinant or animal insulin) may require dose adjustments.

The need for dose adjustment may be necessary as early as the first administration of a human insulin product after an animal insulin product or gradually over a period of weeks or months after transfer. The need for insulin may decrease with insufficient adrenal, pituitary or thyroid function, or with renal or hepatic insufficiency. In some diseases or with emotional stress the need for insulin may increase.

Dose adjustment may also be necessary if physical activity increases or if the usual diet changes.

The precursor symptoms of hypoglycemia on human insulin administration in some patients may be less pronounced or different from those seen in patients on animal insulin administration. When blood glucose levels normalize, e.g. as a result of intensive insulin therapy, all or some of the precursor symptoms of hypoglycemia may disappear, and patients should be informed about it. Hypoglycemic precursor symptoms may change or be less pronounced in the long-term course of diabetes mellitus, diabetic neuropathy or with the simultaneous use of beta-adrenoblockers.

In some cases, local allergic reactions may be due to causes unrelated to the action of the drug, such as skin irritation by a cleansing agent or improper administration of injections.

In rare cases of systemic allergic reactions, immediate treatment is required. Sometimes it may be necessary to change insulin or perform desensitization.

The need for insulin may decrease with hepatic insufficiency. Insulin requirement may decrease in renal insufficiency.

Impact on driving and operating machinery:

During hypoglycemia, the patient may have impaired ability to concentrate and decreased speed of psychomotor reactions. This may be dangerous in situations in which these abilities are especially necessary (driving or operating machinery). Patients should be advised to take precautions to avoid hypoglycemia while driving. This is especially important for patients with mild or absent symptoms-predictors of hypoglycemia or with frequent development of hypoglycemia. In such cases, the physician should evaluate whether it is appropriate for the patient to drive.

Contraindications

– Hypoglycemia.

– Hypersensitivity to insulin or to one of the drug components.

Side effects

A side effect associated with the main effect of the drug: hypoglycemia. Severe hypoglycemia may lead to loss of consciousness and (in exceptional cases) to death.

Allergic reactions: local allergic reactions are possible – hyperemia, swelling or itching at the injection site (usually stops within a few days to a few weeks); systemic allergic reactions (occur less frequently, but are more serious) – generalized itching, difficulty in breathing, shortness of breath, decreased BP, pulse rate, increased sweating. Serious cases of systemic allergic reactions may be life-threatening.

Others: the possibility of developing lipodystrophy is minimal.

Overdose

Symptoms: hypoglycemia accompanied by lethargy, increased sweating, tachycardia, pale skin, headache, shivering, vomiting, confusion. Under certain conditions, such as long duration or intensive control of diabetes mellitus, the precursor symptoms of hypoglycemia may change.

Treatment: mild states of hypoglycemia can usually be controlled by oral glucose (dextrose) or sugar. Adjustment of insulin dose, diet or physical activity may be necessary. Correction of moderate hypoglycemia can be carried out with an injection of glucagon, followed by ingestion of carbohydrates.

Severe states of hypoglycemia accompanied by coma, seizures or neurological disorders are corrected by intravenous or p/c injection of glucagon or intravenous infusion of concentrated glucose solution (dextrose). After recovery of consciousness, the patient should be given food rich in carbohydrates, in order to avoid recurrence of hypoglycemia.